Anti-GPC3 Antibody (YP7)
Based on 1 Customer Validation
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1 κ chimeric antibody, targeting to human GPC3. Anti-GPC3 Antibody (YP7) reacts with the C-lobe of cell surface-associated glypican-3 (GPC3). Anti-GPC3 Antibody (YP7) can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
For research use only. We do not sell to patients.
- Purity : ≥95.0%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Mouse IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
GPC3
In Vitro
Anti-GPC3 Antibody (YP7) (1 μg/mL) has excellent binding affinity and specificity for the native form of GPC3 in hepatocellular carcinoma (HCC) and other GPC3-expressing cancers[1].
Anti-GPC3 Antibody (YP7) (IR700-YP7, IR700 and YP7 conjugation) (10 μg/mL, 6 h) induces lysosome swelling, budding and rupture in A431/G1 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Anti-GPC3 Antibody (YP7) (IR700-YP7, IR700 and YP7 conjugation) (100 μg, i.v.) inhibits tumor growth companied with NIR light in A431/G1 tumor mice (homozygote athymic nude mice)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HepG2 tumor mice models (4-6 weeks, female, BALB/c nu/nu mice)[1]
-
Dosage:5 mg/kg
-
Administration:Intravenously injection, twice a week for 2 weeks
-
Result:Inhibited tumor growth.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
in vitro photoimmunotherapy; in vivo anti-tumor activity; in vivo imaging; in vivo photoimmunothe
Verified Bioactivity
-
Flow cytometric analysis of 1X106 Jurkat cells labeling Anti-GPC3 Antibody (HY-P99840, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Mouse IgG H&L (HY-P8005) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG1 kappa (HY-P99977, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-GPC3 Antibody (YP7)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Phung Y, et al. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. MAbs. 2012 Sep-Oct;4(5):592-9. [Content Brief]
[2]. Hanaoka H, et al. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine (Lond). 2015;10(7):1139-47. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-GPC3 Antibody (YP7) Related Classifications
HY-P990840 Related Classifications
Powered by Bioz